Profile
Sector:
HealthcareIndustry:
Medical Instruments & SuppliesCountry:
CanadaIPO:
06 May 2022Website:
http://www.bausch.comNext earnings report:
02 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Mon, 01 Jul 2024 23:07:42 GMTDividend
Analysts recommendations
Institutional Ownership
BLCO Latest News
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the presentation of several scientific presentations and educational events during the European Dry Eye Society (EuDEC) 2024 Congress, which will take place in Madrid, Spain, June 20-22. Data presentations highlight the results of several studies evaluating consumer, pharmaceutical and vision care products from.
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “Company”), a leading global eye health company dedicated to helping people see better to live better, today announced the election of the 10 directors nominated at its 2024 annual meeting of shareholders (the “Annual Meeting”) held on May 29, 2024. The detailed results of the vote for the election of directors are set out below: Name For Against Broker Non-Votes Nathalie Bernier 344,550,519 28.
Bausch + Lomb Corporation (NYSE/TSX: BLCO), a global eye health company committed to improving people's vision and quality of life, will announce its first-quarter 2024 financial results on May 1, 2024. A conference call and live webcast will be held at 8 a.m. ET to discuss the results and provide a business update. All relevant materials will be posted on the Investor Relations section of the Bausch + Lomb website before the event.
Bausch + Lomb (BLCO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Bausch + Lomb (BLCO) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Bausch + Lomb Corporation (BLCO) Q4 2023 Earnings Call Transcript
Although the revenue and EPS for Bausch + Lomb (BLCO) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Bausch + Lomb Corp.'s stock soared 10% early Wednesday, after the vision-care company's adjusted fourth-quarter profit topped estimates and it offered upbeat revenue guidance for 2024.
Besides Wall Street's top -and-bottom-line estimates for Bausch + Lomb (BLCO), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2023.
Bausch + Lomb (BLCO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
What type of business is Bausch Lomb?
Bausch + Lomb Corporation operates as an eye health company worldwide. It operates through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, and dry eye. The Ophthalmic Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of eye conditions, such as glaucoma, ocular hypertension, and retinal diseases; and contact lenses for therapeutic use. The Surgical segment provides tools and technologies for the treatment of cataracts, and vitreous and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices. The company was founded in 1853 and is headquartered in Vaughan, Canada.
What sector is Bausch Lomb in?
Bausch Lomb is in the Healthcare sector
What industry is Bausch Lomb in?
Bausch Lomb is in the Medical Instruments & Supplies industry
What country is Bausch Lomb from?
Bausch Lomb is headquartered in Canada
When did Bausch Lomb go public?
Bausch Lomb initial public offering (IPO) was on 06 May 2022
What is Bausch Lomb website?
https://www.bausch.com
Is Bausch Lomb in the S&P 500?
No, Bausch Lomb is not included in the S&P 500 index
Is Bausch Lomb in the NASDAQ 100?
No, Bausch Lomb is not included in the NASDAQ 100 index
Is Bausch Lomb in the Dow Jones?
No, Bausch Lomb is not included in the Dow Jones index
When does Bausch Lomb report earnings?
The next expected earnings date for Bausch Lomb is 02 August 2024